IMMUNOCORE HOLDINGS PLC (IMCR)
Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma
Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma
📈 **POSITIVE** • High confidence analysis (85%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (93%) **Content type:** Clinical